Skip to main content
OpenTrials
Completed

NCT Number: NCT04550702

Predictors for Retreatement of OAB After DC Mirabegron

Recurrence of female overactive bladder syndrome (OAB) is not uncommon. It is important to decrease the recurrence of female OAB. However, factors predicting recurrence of female OAB, especially for those women who need retreatment is undetermined. Thus, the aim of this study was to elucidate factors predicting retreatment of female OAB.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Recurrence of Overactive Bladder Syndrome

Age range

20 year–85 year

Sex eligibility

Female

Study type

Observational

Primary location

National Taiwan University Hospital

Taipei, 100, Taiwan

About this study

The medical records, including pad testing, urodynamic studies, lower urinary tract symptoms related questionnaires and bladder diaries of all consecutive women with OAB, who visited urogynecologic clinics in a tertiary referral center, were reviewed. Persistence interval was defined from the date of prescription of mirabegron to the date of discontinuation of mirabegron treatment. Statistical analysis was performed with Kaplan-Meier estimator. Multivariable Cox proportional-hazard model with all variables with p < 0.25 in the univariate analysis was performed to predict OAB retreatment probability.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women with overactive bladder syndrome
  • Women complete urodynamic study and bladder diary

Exclusion criteria

  • Pregnant women
  • Incomplete data
  • Loss of follow-up
  • Acute or chronic urinary tract infection

Treatment and study plan

Mirabegron 25mg

Drug

Mirabegron 25 mg per day

Other names: Betmiga

Primary outcomes

  1. Recurrent OAB

    Time frame: January 2015 to July 2019

    Recurrent OAB with needs to retreatment

Sponsors and collaborators

Lead sponsor

National Taiwan University Hospital

Other

Registry information

Official study title

Predictor for Re-treatment of Overactive Bladder Syndrome After Discontinuation of Mirabegron Treatment for Female Overactive Bladder Syndrome

Important dates

Study start
2015
Primary completion
2019
Study completion
2019
First posted
Sep 16, 2020
Registry last updated
Sep 16, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.